Research programme: Nrf2 activators - Cureveda/GlaxoSmithKline

Drug Profile

Research programme: Nrf2 activators - Cureveda/GlaxoSmithKline

Alternative Names: VEDA-1209

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cureveda; GlaxoSmithKline
  • Developer Cureveda; Georgia State University; GlaxoSmithKline; Johns Hopkins University; Temple University
  • Class Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ulcerative colitis
  • Research Multiple sclerosis; Radiation injuries
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
  • 08 Dec 2014 Cureveda received STTR grant from the National Institutes of Health for VEDA 1209 development in systemic sclerosis and chronic obstructive pulmonary disease
  • 17 Jul 2013 Cureveda receives SBIR grant from National Institutes of Health for VEDA 1209 development in Ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top